Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 29, 2015 2:32 AM ET

Pharmaceuticals

Company Overview of Hovione FarmaCiencia SA

Company Overview

Hovione FarmaCiencia SA develops and manufactures active pharmaceutical ingredients (APIs) and intermediate drug products for the pharmaceutical industry in the United States and other North American countries, Europe, and Japan. The company specializes in chemistry and particle engineering. It offers services related to the development, manufacture, and pre-formulation of new chemical entities and existing APIs for off-patent products; NavStream, a read only Internet based management tool that enables selective access to GMP data referent to development project or production line at Hovione; and project management services. The company also provides custom synthesis services in the areas of...

Sete Casas

Loures,  2674-506

Portugal

Founded in 1959

Phone:

351 21 982 9000

Fax:

351 21 982 9388

Key Executives for Hovione FarmaCiencia SA

Chief Executive Officer and Director
Chief Financial Officer and Vice President of Finance
Age: 58
Vice President of Sales & Business Development and President of Us Operations
Head of Particle Design Sciences In New Jersey
Director of Corporate Communications
Compensation as of Fiscal Year 2014.

Hovione FarmaCiencia SA Key Developments

Hovione Appoints Filipe Gaspar as Vice President R&D

Hovione announced the appointment of Dr. Filipe Gaspar as Vice President of its Research and Development organization. Dr. Gaspar will lead teams based in Lisbon and New Jersey that serve clients' drug development projects; he will also be defining long-term product development strategies and collaborations. He will report to Guy Villax, Hovione's Chief Executive. Dr. Gaspar joined Hovione in 2003 as a Manufacturing engineer and later became responsible for the technical leadership of spray drying technology. In 2004 Dr. Gaspar moved to R&D to start the Particle Engineering group, there he was involved in more than 120 projects from preclinical stage to commercial. During that period he was the Lead Scientist in four projects that reached commercial stage, including the first at Hovione submitted under Quality by Design. He was instrumental in many of the projects that have contributed to Hovione's growing success in Particle Engineering. In 2012 he moved to a Business Development role and spent a year based in New Jersey.

Hovione Submits First Investigational New Drug Application for Minocycline to United States Food and Drug Administration

The United States Food and Drug Administration has received Hovione's first investigational new drug application for minocycline gel to administer topically for acne. The filing is a part of the company's strategy to develop improved drug delivery options for established drugs. After receiving United States Food and Drug Administration's acceptance of the investigational new drug application submission, the firm plans to commence human clinical phase I/II trials in early 2015.

Anacor Pharmaceuticals, Inc. Enters Into Manufacturing Agreement with Hovione FarmaCiencia SA

On September 30, 2014, Anacor Pharmaceuticals Inc. entered into a manufacturing agreement with Hovione FarmaCiencia SA, pursuant to which Hovione will manufacture and supply to the company Tavaborole active pharmaceutical ingredient (API) for the company's drug KERYDINTM (tavaborole) topical solution, 5%. Pursuant to the agreement, the company is obligated during the term to purchase from Hovione a portion of its API requirements for KERYDIN intended for distribution in the United States. The company may qualify and, subject to certain limitations, purchase a portion of its API requirements for KERYDIN from an alternate supplier during the term of the Agreement. The purchase price for the API is fixed subject to potential periodic adjustment over the term of the agreement. The agreement will continue for an initial term expiring on December 31, 2020 and is subject to automatic 18-month renewal terms, unless earlier terminated by either party on at least 18 months' written notice prior to the end of the initial term (or any such renewal term) or for specified events under the agreement. Either party may terminate the agreement for uncured material breaches by the other party or in the event of the bankruptcy or insolvency of the other party. In addition, the company may terminate the agreement in the event that KERYDIN's new drug application is withdrawn or Hovione is unable, in certain circumstances, to satisfy the company's purchase requirements. Prior to January 31, 2018, Hovione may give notice to the company to terminate the agreement effective December 31, 2018 in the event that the company does not make aggregate purchases of API for KERYDIN from Hovione in excess of a certain minimum amount.

Similar Private Companies By Industry

Company Name Region
Grunenthal S.A. Europe
Bial - S.G.P.S., S.A. Europe
Atlantic Pharma S.A. Europe
Schering-Plough Farma Lda. Europe
BioSaúde Produtos Farmacêuticos Lda Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hovione FarmaCiencia SA, please visit www.hovione.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.